ANTI-IMP TYPE CARBAPENEMASE HYBRIDOMA CELL STRAIN, MONOCLONAL ANTIBODY AND USE

Title:

ANTI-IMP TYPE CARBAPENEMASE HYBRIDOMA CELL STRAIN, MONOCLONAL ANTIBODY AND USE

Document Type and Number:

WIPO Patent Application WO/2022/166353

Kind Code:

A1

Abstract:

Provided is an anti-IMP type carbapenemase hybridoma cell strain. The hybridoma cell strain capable of stably secreting an anti-IMP type carbapenemase antibody and a variable region sequence thereof are obtained by means of screening a mouse hybridoma monoclonal antibody and cloning an Ig variable region gene by means of an RT-PCR method, and the antibody binding specificity is identified by means of an ELISA method; the antibody can be used for detecting IMP type carbapenemase, the titer reaches 1:640000 or more, and same can be prepared into an in-vitro diagnostic kit or microfluidic chip for early typing of drug-resistant strains, guiding medication and assisting clinical infection control and treatment.

Inventors:

YUAN QINGHUA (CN)
HE YONGSHENG (CN)
LI KEKE (CN)
CHEN XIAOLING (CN)
ZHOU YUEHUI (CN)
FAN LINLIN (CN)
WANG YUFANG (CN)
ZANG DANRONG (CN)

Application Number:

PCT/CN2021/135403

Publication Date:

August 11, 2022

Filing Date:

December 03, 2021

Export Citation:

Click for automatic bibliography generation Help

Assignee:

TIANJIN ERA BIOLOGY TECH CO LTD (CN)
BEIJING GOLD MOUNTAINRIVER TECH DEV CO LTD (CN)

International Classes:

C12N5/20; C07K16/40; C12N15/13; G01N33/573; G01N33/577

Domestic Patent References:

WO2016092096A1

2016-06-16

Foreign References:

CN107667291A	2018-02-06
US20120219952A1	2012-08-30
CN112501131A	2021-03-16
CN112500489A	2021-03-16

Other References: